Abstract
Pediatric antiretroviral treatment programs have been rolled out in resource limited settings, providing lifesaving treatment to approximately 300,000 HIV-infected children. The standard first-line antiretroviral regimen is a nonnucleoside reverse transcriptase plus 2 nucleoside reverse transcriptase inhibitors (NRTIs). A meta-analysis showed that 70% of children achieved virologic suppression after 12 months of first line therapy. This article presents the challenges in diagnosis of treatment failure in resource limited settings and reviews the current guidelines for management of HIV-infected children with second-line antiretroviral therapy. The details of antiretroviral drugs recommended for second line regimens are summarized. The current standard second-line regimen is a boostedprotease inhibitor-based regimen plus recycling NRTIs. The potential role of new ARV drug classes for second-line regimen is addressed.
Keywords: Pediatric HIV, antiretroviral therapy, resource limited settings
Current Pediatric Reviews
Title: Second-Line Antiretroviral Therapy for HIV-Infected Children in Resource Limited Settings
Volume: 7 Issue: 3
Author(s): Linda Aurpibul and Thanyawee Puthanakit
Affiliation:
Keywords: Pediatric HIV, antiretroviral therapy, resource limited settings
Abstract: Pediatric antiretroviral treatment programs have been rolled out in resource limited settings, providing lifesaving treatment to approximately 300,000 HIV-infected children. The standard first-line antiretroviral regimen is a nonnucleoside reverse transcriptase plus 2 nucleoside reverse transcriptase inhibitors (NRTIs). A meta-analysis showed that 70% of children achieved virologic suppression after 12 months of first line therapy. This article presents the challenges in diagnosis of treatment failure in resource limited settings and reviews the current guidelines for management of HIV-infected children with second-line antiretroviral therapy. The details of antiretroviral drugs recommended for second line regimens are summarized. The current standard second-line regimen is a boostedprotease inhibitor-based regimen plus recycling NRTIs. The potential role of new ARV drug classes for second-line regimen is addressed.
Export Options
About this article
Cite this article as:
Aurpibul Linda and Puthanakit Thanyawee, Second-Line Antiretroviral Therapy for HIV-Infected Children in Resource Limited Settings, Current Pediatric Reviews 2011; 7 (3) . https://dx.doi.org/10.2174/157339611796548375
DOI https://dx.doi.org/10.2174/157339611796548375 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Use of Protein Tyrosine Phosphatase Inhibitors as Promising Targeted Therapeutic Drugs
Current Medicinal Chemistry Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Type 2 Diabetes and Obesity Metabolic Interactions: Common Factors for Breast Cancer Risk and Novel Approaches to Prevention and Therapy
Current Diabetes Reviews Peroxisome Proliferator-Activated Receptors and their Ligands in Cancer Drug- Resistance: Opportunity or Challenge
Anti-Cancer Agents in Medicinal Chemistry Approaches for the Development of Drugs for Treatment of Obesity and Metabolic Syndrome
Current Pharmaceutical Design Characterizing Protein Structure, Dynamics and Conformation in Lyophilized Solids
Current Pharmaceutical Design The Concomitance of Hypertension and Diabetes Exacerbating Retinopathy: The Role of Inflammation and Oxidative Stress.
Current Clinical Pharmacology Insulin Resistance as Common Molecular Denominator Linking Obesity to Alzheimer’s Disease
Current Alzheimer Research Nanoliposomes of Supercritical Carbon Dioxide Extract of Small Cardamom Seeds Redresses Type 2 Diabetes and Hypercholesterolemia
Recent Patents on Biotechnology Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review
Current Vascular Pharmacology Type 2 Diabetes Mellitus and the Elderly: An Update on Drugs Used to Treat Glycaemia
Current Vascular Pharmacology Gene Therapy for Type I Glycogen Storage Diseases
Current Gene Therapy Nutritional Programming of Foetal Development: Endocrine Mediators and Long-Term Outcomes for Cardiovascular Health
Current Nutrition & Food Science Bacterial Protein Toxins: Current and Potential Clinical Use
Current Medicinal Chemistry Oxidative Modification of Lipoproteins: Mechanisms, Role in Inflammation and Potential Clinical Applications in Cardiovascular Disease
Current Pharmaceutical Design Intra-arterial Instillation of a Nociceptive Agent Modulates Cardiorespiratory Parameters Involving 5-HT3 and TRPV1 Receptors in Anesthetized Rats
Cardiovascular & Hematological Disorders-Drug Targets Pharmacological Modulation of Microparticle Release: New Strategies for the Management of Atherothrombotic Vascular Disorders
Current Pharmaceutical Design Update on the Role of Neutrophils in Atherosclerotic Plaque Vulnerability
Current Drug Targets Editorial [Hot Topic: Advances in Diagnosing Drug Hypersensitivity Reactions (Executive Editors: A. Romano and M. Ventura)]
Current Pharmaceutical Design Epstein-Barr Virus-associated Gastric Cancer and Potential Mechanisms of Oncogenesis
Current Cancer Drug Targets